Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/22
February 10, 2014

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

The National Stock Exchange of India Limited
Exchange Plaza
Bandra – Kurla Complex
Bandra (East)
Mumbai- 400 051

"By Email & Courier"

Kind Attn: **Mr. Hari K.**

Subject: Intimation of Company Statement to Media

In response to a media query with respect to the legal action pursued by Roche Products (India) Private Limited on the launch of Biosimilar Trastuzumab [Refer the press Release by Company on January 18, 2014], the Company clarifies below:

"It is an extremely shocking, but not unexpected development especially as Roche had decided not to pursue Indian patents for their breast cancer drug. This proceeding is an attempt by Roche to protect their market monopoly and prevent Indian patients from accessing a more affordable trastuzumab. CANMAb™ and HERTRAZ ™ co-developed by Biocon and Mylan are world-class products that adhere to stringent quality standards and have been developed on the basis of applicable biosimilar guidelines. Biocon and Mylan are committed to affordability & access and are driven by their purpose of expanding the pool of patients that can afford trastuzumab. We are confident that once we are heard by the court, this injunction placing certain limits on promotional activities will not stand. "

Kindly take this intimation on record.

Thanking you.

Yours faithfully,
For Biocon Limited,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By Fax to NSE: 022 – 2659 8237 / 38
By Email to NSE: cmlist@nse.co.in